For MET, for example, in a phase I clinical trial testing the humanized anti-MET antibody Onartuzumab, patients with metastatic, chemotherapy-resistant gastric carcinomas, and high MET expression (defined qualitatively as > 50% of tumor cells with 2+ and 3+ staining) showed complete response with improved progression free survival (PFS) and overall survival (OS) [34]. The gene discussed is MET; the disease is gastric carcinoma.